How the complex pharmacology of the fentanyls contributes to their lethality by Henderson, Graeme et al.
                          Henderson, G., Kelly, E., & Gill, H. (2019). How the complex pharmacology
of the fentanyls contributes to their lethality. Addiction.
https://doi.org/10.1111/add.14614
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1111/add.14614
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via Wiley at
https://onlinelibrary.wiley.com/doi/full/10.1111/add.14614 . Please refer to any applicable terms of use of the
publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
How the complex pharmacology of the fentanyls
contributes to their lethality
Fentanyls as a class of drug have pharmacological properties
that make them more likely to lead to overdose than other
opioids. In addition to high potency and rapid onset of
respiratory depression, these drugs also induce respiratory
muscle stiffness, making it more difﬁcult to breathe, are less
sensitive than heroin to naloxone reversal and may show
reduced cross-tolerance to other opioids.
Overdose deaths involving fentanyls (fentanyl and struc-
turally related opioid drugs) have risen dramatically in
North America during the last few years [1], while the rest
of the world waits nervously to see if this epidemic will
spread globally.
Heroin and other opioids depress respiration by acting
on μ opioid receptors (MORs) to reduce the response to
raised partial pressure of carbon dioxide (pCO2) and lowered
partial pressure of oxygen (pO2), and thus reduce the drive
to breathe. Given the high death rate involving fentanyl
overdose the question arises of whether the lethality of
fentanyls results simply from their high potency or whether
other pharmacological properties also contribute.
Fentanyls are relatively selective and potent agonists at
MORs, with fentanyl and carfentanil being, respectively,
~×50 and ~×10000 more potent than morphine [2,3].
Such high potency means that only small amounts of drug
are required to produce respiratory depression, and thus
even a minor error could result in too much being taken.
Fentanyls are highly lipid soluble molecules and readily
penetrate into the brain, resulting in overdose levels being
reached rapidly. Deaths in heroin overdose may take more
than 30 minutes to occur after injection [4], providing a
window of opportunity for intervention (administration of
the antagonist naloxone). In contrast, fentanyl overdose
deaths can occur very quickly, within 5 minutes, poten-
tially before remedial action can be taken [5,6].
In recent years there has been enormous interest
within the pharmacological community in the phenome-
non of biased agonism, whereby agonists acting at the
same receptor may activate one downstream signalling
pathway more strongly over another [7]. Activation of
MOR results in downstream signalling through either G
protein or arrestin pathways. It has been claimed that re-
spiratory depression results from opioid signalling through
arrestins [8] and that fentanyl is arrestin-biased, thus
explaining its greater ability to depress respiration than
heroin [9]. The view that respiratory depression by opioids
is mediated by arrestin signalling and that fentanyl is
arrestin-biased is, however, highly contentious. We did
not ﬁnd fentanyl to be arrestin-biased in our extensive
analysis of bias at MOR [10], while in a recent study on
transgenic mice, in which the MOR could not signal
through arrestins, morphine still depressed respiration [11].
In humans, intravenous administration of fentanyls
can produce skeletal muscle rigidity [4,12,13]. Animal
studies show that fentanyls produce muscle rigidity by act-
ing on MORs in various brain regions to enhance motor
neurone activity [14]. Recently, signs of muscle rigidity
have been observed in users at a supervised drug injection
facility who have presumably injected illicit fentanyls [15].
Skeletal muscle rigidity produces stiffness of the chest
wall, referred to colloquially as ‘wooden’ chest. Someone
injecting illicit fentanyls may therefore experience the
double whammy of a depressed respiratory drive and a
mechanical restriction to breathing. Muscle rigidity may
also reduce the effectiveness of cardiopulmonary resuscita-
tion. Another consequence of muscle rigidity is that, unlike
the characteristic slouching that occurs in heroin over-
dose, in fentanyl overdose the subject can remain upright
and those nearby may be unaware that an overdose has
occurred, and where help is summoned those attending
may not initially associate body rigidity with opioid over-
dose [15].
There is increasing awareness that respiratory depres-
sion by fentanyls is harder to reverse with naloxone than
that by other opioids such as heroin, and may
require multiple or higher doses of naloxone [16–18].
Why this should be is unclear, and has mistakenly been
attributed to fentanyls having high afﬁnity of binding at
MOR. It is a fundamental tenet of pharmacology that
under equilibrium-competitive conditions the degree of
antagonism observed depends solely upon the antagonist’s
afﬁnity and concentration and is independent of the
agonist’s afﬁnity of binding; i.e. agonists of different afﬁnity
should be reversed equally. That fentanyls are less readily
reversedmay indicate that, due to their high lipid solubility,
they have atypical micro-pharmacokinetic proﬁles that
enhance the agonist:antagonist concentration ratio in the
vicinity of the receptors, thus preventing equilibrium com-
petition from taking place, or that they interact with MOR
in a novel way that reduces the ability of naloxone to dis-
place them.
In treating heroin overdose the aim has been to keep
the dose of naloxone low, administering enough to reverse
respiratory depression without precipitating withdrawal
symptoms. Further doses of naloxone can be administered
if respiration fails to recover. When fentanyl overdose is
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suspected it may be expedient to rapidly increase the dose
of naloxone to reverse the respiratory depression [16].
Tolerance develops to the respiratory depressant ef-
fects of opioids. Cross-tolerance develops between opioid
drugs acting at the same receptor, but the degree of
cross-tolerance will depend upon agonist intrinsic efﬁ-
cacy. In a rodent model measuring opioid-induced loco-
motor activity, prolonged treatment with morphine
produced a 22-fold increase in the 50% effective dose
(ED50) for morphine but only a fourfold increase in the
ED50 for fentanyl [19]. Most of the fentanyls have high
intrinsic efﬁcacy (ability to produce a response once
bound to the receptor) and so need to occupy only a
small proportion of the available receptors to produce
that response. This suggests that they are less likely to
be affected by the loss of receptor function that underlies
heroin tolerance and are able to ‘break through’ heroin-
induced tolerance and produce respiratory depression
even in heroin-tolerant individuals. The low level of
cross-tolerance with heroin may be exacerbated by
fentanyls also producing chest wall rigidity. As heroin in-
duces little or no chest wall rigidity it is unlikely that tol-
erance to this effect will have developed in heroin users.
A combination of factors—potency, rate of onset, bias,
muscle rigidity, lower susceptibility to naloxone reversal,
lack of cross-tolerance—may conspire together to make
fentanyls such lethal drugs. We would suggest that the
dangers of fentanyls will only be fully understood and then
mitigated by rigorously applying pharmacological princi-
ples to both experimental and clinical data.
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